This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pritchard, K. I. Articles by Dhesy-Thind, B. Search for Related Content PubMed PubMed Citation Articles by Pritchard, K. I. Articles by Dhesy-Thind, B. Related Articles Related Correspondence Social Bookmarking                            What's this?

HER-2 and Topoisomerase II As Predictors of Response to Chemotherapy

Kathleen I. Pritchard, Hans Messersmith, Leela Elavathil, Maureen Trudeau, Frances O’Malley, Bindi Dhesy-Thind

From the Sunnybrook Odette Cancer Centre; Department of Pathology and Laboratory Medicine, Mount Sinai Hospital; Cancer Care; Departments of Medicine and Pathology and Laboratory Medicine, University of Toronto; Ontario, Toronto; McMaster University; Henderson Hospital; and Juravinski Cancer Centre, Hamilton, Ontario, Canada

Corresponding author: Kathleen I. Pritchard, MD, FRCPC, FACP, Sunnybrook Odette Cancer Centre, Department of Medicine, University of Toronto, 2075 Bayview Ave, Toronto, ON M4N 3M5; e-mail: kathy.pritchard{at}sunnybrook.ca

HER2 overexpression or amplification has been shown to be associated with a poor prognostic effect in women with breast cancer. At least eight analyses based on randomized trials have examined the relationship between HER2 and the differential effect of anthracycline compared with non–anthracycline-containing regimens. Only three of these studies were sufficiently powered to show a significant interaction between HER2 and anthracycline- versus non–anthracycline-containing treatments, but because all of the study results tended to be in the same direction, it is not surprising that three recent meta-analyses of published data have suggested that anthracycline-containing regimens provide more benefit than non–anthracycline-containing regimens in women whose tumors are overexpressed or amplified (positive) for HER2. Since topoisomerase II is a known target of the anthracyclines, it has been postulated that this relationship is actually based on the proximity of HER2 to the topoisomerase II gene (TOP2A) in the 17q chromosome. At least four recent studies have suggested that deletion and amplification of the TOP2A gene are associated with poor prognosis and are predictive of greater response to anthracycline-containing than to non–anthracycline-containing regimens. However, in at least one of those studies, HER2 positivity was as or more predictive. Although it has been suggested that HER2 positivity is predictive of better response to higher-dose anthracycline-containing regimens compared with standard anthracycline-containing regimens and to taxane- compared with non–taxane-containing regimens, these relationships have not been robust or consistent. Additional studies will be required to clarify these relationships.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Hormone Receptor, Grade, Human Epidermal Growth Factor Receptor 2, and Topoisomerase II As Predictors of Response to Chemotherapy
  Rita S. Mehta
  JCO 2008 26: 2596 [Full Text]

This article has been cited by other articles:

				J. A. Sparano, L. J. Goldstein, B. H. Childs, S. Shak, D. Brassard, S. Badve, F. L. Baehner, R. Bugarini, S. Rowley, E. Perez, et al. Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer Clin. Cancer Res., December 15, 2009; 15(24): 7693 - 7700. [Abstract] [Full Text] [PDF]

				L. Gianni, L. Norton, N. Wolmark, T. M. Suter, G. Bonadonna, and G. N. Hortobagyi Role of Anthracyclines in the Treatment of Early Breast Cancer J. Clin. Oncol., October 1, 2009; 27(28): 4798 - 4808. [Abstract] [Full Text] [PDF]

				R. Tubbs, W. E. Barlow, G. T. Budd, E. Swain, P. Porter, A. Gown, I-T. Yeh, G. Sledge, C. Shapiro, J. Ingle, et al. Outcome of Patients With Early-Stage Breast Cancer Treated With Doxorubicin-Based Adjuvant Chemotherapy As a Function of HER2 and TOP2A Status J. Clin. Oncol., August 20, 2009; 27(24): 3881 - 3886. [Abstract] [Full Text] [PDF]

				F. J. Esteva and G. N. Hortobagyi Topoisomerase II{alpha} Amplification and Anthracycline-Based Chemotherapy: The Jury Is Still Out J. Clin. Oncol., July 20, 2009; 27(21): 3416 - 3417. [Full Text] [PDF]

				M. Stros, E. Polanska, S. Struncova, and S. Pospisilova HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase II{alpha} Nucleic Acids Res., April 1, 2009; 37(7): 2070 - 2086. [Abstract] [Full Text] [PDF]

				S. Jones, F. A. Holmes, J. O'Shaughnessy, J. L. Blum, S. J. Vukelja, K. J. McIntyre, J. E. Pippen, J. H. Bordelon, R. L. Kirby, J. Sandbach, et al. Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735 J. Clin. Oncol., March 10, 2009; 27(8): 1177 - 1183. [Abstract] [Full Text] [PDF]

				L. Gianni and P. Valagussa Anthracyclines and Early Breast Cancer: The End of an Era? J. Clin. Oncol., March 10, 2009; 27(8): 1155 - 1157. [Full Text] [PDF]

				E. de Azambuja, M. Paesmans, M. Beauduin, A. Vindevoghel, N. Cornez, C. Finet, F. Ries, M. T. Closon-Dejardin, J. Kerger, P. Gobert, et al. Long-Term Benefit of High-Dose Epirubicin in Adjuvant Chemotherapy for Node-Positive Breast Cancer: 15-Year Efficacy Results of the Belgian Multicentre Study J. Clin. Oncol., February 10, 2009; 27(5): 720 - 725. [Abstract] [Full Text] [PDF]

				M. Dowsett and A. K. Dunbier Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer Clin. Cancer Res., December 15, 2008; 14(24): 8019 - 8026. [Abstract] [Full Text] [PDF]

				E. Castro and E. de Alava The risk of taking the part by the whole Ann. Onc., November 1, 2008; 19(11): 1975 - 1976. [Full Text] [PDF]

				S. Menard, A. Balsari, E. Tagliabue, T. Camerini, P. Casalini, R. Bufalino, F. Castiglioni, M. L. Carcangiu, A. Gloghini, S. Scalone, et al. Biology, prognosis and response to therapy of breast carcinomas according to HER2 score Ann. Onc., October 1, 2008; 19(10): 1706 - 1712. [Abstract] [Full Text] [PDF]

				N. C Turner and A. L Jones Management of breast cancer--Part II BMJ, July 11, 2008; 337(jul11_2): a540 - a540. [Full Text]

				J. Peppercorn and A. H. Partridge Breast Cancer in Young Women: A New Color or a Different Shade of Pink? J. Clin. Oncol., July 10, 2008; 26(20): 3303 - 3305. [Full Text] [PDF]

				R. S. Mehta Hormone Receptor, Grade, Human Epidermal Growth Factor Receptor 2, and Topoisomerase II As Predictors of Response to Chemotherapy J. Clin. Oncol., May 20, 2008; 26(15): 2596 - 2596. [Full Text] [PDF]